Inflexion carves out GFK’s animal and crop health business

The buyout saw Inflexion invest alongside the existing management team. GFK is exiting the business due to a change in strategy. The transaction is expected to close during Q1 2016.

The MBO is Inflexion's second carve-out this month: at the start of November, the GP acquired the engineering inspection and consultancy division of RSA.

Company
GFK's animal and crop health business delivers market information to the agriculture and animal health markets, providing insights into their customers' growth requirements. The business delivered sales of $40m in 2014 and employs 220 people in 18 countries.

People
Mark Williams is an investment director at Inflexion. Stephen Hearn is GFK's global director of the animal and crop health business.

Advisers
Equity – Plural Strategy Group (Commercial due diligence).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• DACH
• Buyouts
• Support services
• UK / Ireland
• Germany
• United Kingdom